Antimicrobial Stewardship

Antibiotic-resistant strains of the dangerous superbug C difficile have been identified in pigs and humans, suggesting zoonotic transmission is possible.

In the latest column from SIDP, clinicians discuss that along with the once-daily dosing for many indications, there are also compelling indications for twice-daily dosing.

Improving stool sample collecting and testing reduced C difficile underdiagnosis.

Researchers sought to assess antibiotic prescriptions associated with COVID-19 outpatient visits in Medicare beneficiary patients over the course of a year during the pandemic.

Investigators performed a systematic review to assess just how strong the association between race and urinary tract infections (UTIs) in children.

Antibiotic overuse is a longstanding problem in the medical community. A new study highlights the benefits of accurate point-of-care testing to differentiate between bacteria and viruses.

Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.

During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.

Although the development of antibiotics remains a challenge, there are some legislative strategies that could make it more attractive and get more players involved.

The tactic is seen as a way to ensure supplies of novel drugs in face of resistance crisis.

Investigators used procalcitonin (PCT) levels to guide antibiotic recommendations in pediatric intensive care units. PCT-guided antibiotic stewardship decreased the number of antibiotic days without leading to therapy failure.

Critical care pharmacists and PGY2CC residents made fewer antimicrobial stewardship interventions on the Mondays following weekends they worked.

Antimicrobial stewardship efforts, such as education for healthcare providers, significantly decreased community-acquired pneumonia antibiotic prescriptions in COVID-19 patients.

Selecting initial antibiotic for ventilator-associated pneumonia from Gram staining and resistance records could reduce broad spectrum agents.

A survey’s results show updating programs is largely dependent on resources and dedicated personnel.

A study found that hospital providers who prescribe unnecessarily high rates of antibiotics are likely to continue doing so over time.

A large veterans health administration study estimated antibiotic use during the last 6 months of life for patients under hospice or palliative care.

The risk of a community-acquired C difficile infection was 7-fold higher for outpatients with antibiotic exposure.

During the COVID-19 pandemic, use of community-acquired pneumonia antibiotics increased significantly, while relative utilization of carbapenems decreased.

Company is working towards full Food and Drug Administration approval in the coming months.

As this is National Public Health Week, and COVID-19 is still top of mind for clinicians and public health officials, what is it going to take for it to become a secondary issue.

Bedaquiline-resistant tuberculosis is characterized in South Africa, where it has not been reserved as last resource for drug-resistant TB.

Surveillance of N meningitidis finds that resistance is rare, with intermediate susceptibility to penicillin consistent year-to-year.

The Center for Global Development is launching a new working group, which aims to address antimicrobial resistance by exploring how to improve incentives for pharmaceutical companies to develop new antimicrobials for low-income and middle-income countries (LMICs).

Both noncarbapenem β-lactams and carbapenems produced good outcomes in UTI from β-lactamase-producing Enterobacterales.

Series-specific antibiotics can be far less effective if there are other microbes present.

Engaging in antimicrobial stewardship programs led to a reduction in antibiotic usage in long-term care facilities, potentially reducing the growing risk of antibiotic resistance.

The phase 3 results for its antibiotic, cefepime-taniborbactam, demonstrated it met its primary endpoint and the company says it is on track for a fourth quarter 2022 FDA NDA.

Using real-time genetic surveillance, investigators found bacterial infections rapidly develop resistance to antibiotics, only to have these gene mutations disappear within a few days of switching to a different treatment.

Few patients hospitalized for COVID-19 developed concurrent infectious diseases or required antibiotics.